Robert Bazemore

Rob joined the Ardelyx board of directors in June 2016. Rob served as President and chief executive officer and a director of Epizyme, a biopharmaceutical company, from September 2015 until the company was acquired by Ipsen in August 2021. Prior to joining Epizyme, Rob served as chief operating officer of Synageva BioPharma, which was acquired by Alexion Pharmaceuticals in July 2015. Earlier in his career, Rob was president of Janssen Biotech, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Rob currently serves on the board of directors of Nuvation Bio. He also served on the board of directors of Neon Therapeutics, Inc. from November 2018 to its acquisition by Biopharmaceuticals New Technologies, or BioNTech, in May 2020.

He received his B.S. in Biochemistry from the University of Georgia.